Top Markets
#1 Black Phoenix Black Phoenix +733.92%
#2 Biconomy Biconomy +28.18%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.97%
#4 TENDIES TENDIES +21.95%
#5 MetaDAO MetaDAO +19.52%
#6 THORChain THORChain +19.00%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +17.65%
#8 Moolah Moolah +16.24%
#9 Pons Pons +13.92%
#10 THORChain Yield THORChain Yield +13.85%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Keymed Biosciences Inc. Keymed Biosciences Inc.

Keymed Biosciences Inc.

2162
Kedudukan dalam Saham #5165
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Harga Saham
$9.91
Modal Pasaran
$2.92B
Perubahan (1 hari)
-3.25%
Perubahan (1 tahun)
16.09%
Negara
CN
Perdagangan Keymed Biosciences Inc. (2162)

Kategori

Healthcare
Sejarah hasil dividen untuk Keymed Biosciences Inc. (2162)
Hasil dividen (TTM) bagi Keymed Biosciences Inc. (simbol saham: 2162) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Keymed Biosciences Inc. (2162) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
Syarikat Hasil Dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH